These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10753907)

  • 1. Localization of von willebrand factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-to-alanine scanning mutagenesis.
    Matsushita T; Meyer D; Sadler JE
    J Biol Chem; 2000 Apr; 275(15):11044-9. PubMed ID: 10753907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor.
    Matsushita T; Sadler JE
    J Biol Chem; 1995 Jun; 270(22):13406-14. PubMed ID: 7539426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation.
    De Luca M; Facey DA; Favaloro EJ; Hertzberg MS; Whisstock JC; McNally T; Andrews RK; Berndt MC
    Blood; 2000 Jan; 95(1):164-72. PubMed ID: 10607699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the amino acid residues of the platelet glycoprotein Ib (GPIb) essential for the von Willebrand factor binding by clustered charged-to-alanine scanning mutagenesis.
    Shimizu A; Matsushita T; Kondo T; Inden Y; Kojima T; Saito H; Hirai M
    J Biol Chem; 2004 Apr; 279(16):16285-94. PubMed ID: 14757772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease.
    Stepanian A; Ribba AS; Lavergne JM; Fressinaud E; Juhan-Vague I; Mazurier C; Girma JP; Meyer D
    Br J Haematol; 2003 Feb; 120(4):643-51. PubMed ID: 12588351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the structure and function of the von Willebrand factor A1 domain using targeted deletions and alanine-scanning mutagenesis.
    Kroner PA; Frey AB
    Biochemistry; 1996 Oct; 35(41):13460-8. PubMed ID: 8873615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
    Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
    Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding site on human von Willebrand factor of bitiscetin, a snake venom-derived platelet aggregation inducer.
    Matsui T; Hamako J; Matsushita T; Nakayama T; Fujimura Y; Titani K
    Biochemistry; 2002 Jun; 41(25):7939-46. PubMed ID: 12069583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ibalpha. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ibalpha as a binding site for von Willebrand factor and alpha-thrombin.
    Ward CM; Andrews RK; Smith AI; Berndt MC
    Biochemistry; 1996 Apr; 35(15):4929-38. PubMed ID: 8664285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant botrocetin-2 inhibits von Willebrand factor-induced platelet agglutination.
    Matsui T; Hori A; Hamako J; Matsushita F; Ozeki Y; Sakurai Y; Hayakawa M; Matsumoto M; Fujimura Y
    J Thromb Haemost; 2017 Mar; 15(3):538-548. PubMed ID: 28071872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the regulatory elements of the human von Willebrand factor for binding to platelet GPIb. Importance of structural integrity of the regions flanked by the CYS1272-CYS1458 disulfide bond.
    Nakayama T; Matsushita T; Dong Z; Sadler JE; Jorieux S; Mazurier C; Meyer D; Kojima T; Saito H
    J Biol Chem; 2002 Jun; 277(24):22063-72. PubMed ID: 11943773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformational changes in the A3 domain of von Willebrand factor modulate the interaction of the A1 domain with platelet glycoprotein Ib.
    Obert B; Houllier A; Meyer D; Girma JP
    Blood; 1999 Mar; 93(6):1959-68. PubMed ID: 10068669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease.
    Jenkins PV; Pasi KJ; Perkins SJ
    Blood; 1998 Mar; 91(6):2032-44. PubMed ID: 9490688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ristocetin and botrocetin involve two distinct domains of von Willebrand factor for binding to platelet membrane glycoprotein Ib.
    Girma JP; Takahashi Y; Yoshioka A; Diaz J; Meyer D
    Thromb Haemost; 1990 Oct; 64(2):326-32. PubMed ID: 1702906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shielding the front-strand beta 3 of the von Willebrand factor A1 domain inhibits its binding to platelet glycoprotein Ibalpha.
    Bonnefoy A; Yamamoto H; Thys C; Kito M; Vermylen J; Hoylaerts MF
    Blood; 2003 Feb; 101(4):1375-83. PubMed ID: 12393553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
    Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
    Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ristocetin-dependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent interactions.
    Dong JF; Berndt MC; Schade A; McIntire LV; Andrews RK; López JA
    Blood; 2001 Jan; 97(1):162-8. PubMed ID: 11133756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A template-assembled synthetic protein surface mimetic of the von Willebrand factor A1 domain inhibits botrocetin-induced platelet aggregation.
    Hauert J; Fernandez-Carneado J; Michielin O; Mathieu S; Grell D; Schapira M; Spertini O; Mutter M; Tuchscherer G; Kovacsovics T
    Chembiochem; 2004 Jun; 5(6):856-64. PubMed ID: 15174170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet aggregation induced by a monoclonal antibody to the A1 domain of von Willebrand factor.
    Depraetere H; Ajzenberg N; Girma JP; Lacombe C; Meyer D; Deckmyn H; Baruch D
    Blood; 1998 May; 91(10):3792-9. PubMed ID: 9573016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purification of botrocetin from Bothrops jararaca venom. Analysis of the botrocetin-mediated interaction between von Willebrand factor and the human platelet membrane glycoprotein Ib-IX complex.
    Andrews RK; Booth WJ; Gorman JJ; Castaldi PA; Berndt MC
    Biochemistry; 1989 Oct; 28(21):8317-26. PubMed ID: 2557900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.